Skip to main content

TELA Bio, Inc. (TELA)

Sector
Healthcare
Industry
Medical Devices
Last price
$0.76
As of

Kresmion compiles this page from TELA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

TELA Bio, Inc. (TELA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-10.

As of . Source: SEC EDGAR filings for TELA. Method and limitations.

COMPANY DOSSIER

See the full TELA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TELA on one page. Preview it with sample data, then open it live with a free account.

Preview the TELA dossier

Active events for TELA

  • mediumEarnings above estimates

    Q3-2026: Beat consensus by 20.5%, EPS $-0.13 vs $-0.1636 estimate

  • mediumEarnings below estimates

    Q2-2026: Missed consensus by 10.0%, EPS $-0.20 vs $-0.1818 estimate

  • high13F: large reduction

    RENAISSANCE TECHNOLOGIES LLC cut 59% of TELA (2026Q1)

  • mediumEarnings above estimates

    Q3-2025: Beat consensus by 6.4% - EPS $-0.19 vs $-0.203 estimate

  • mediumEarnings below estimates

    Q1-2026: Missed consensus by 9.4% - EPS $-0.21 vs $-0.192 estimate

FREE, NO ACCOUNT

Every event on TELA, as it fires

You are seeing 5 of 9 events recorded on TELA since 2026-05-30.

The five above landed across 4 days. The other 4 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, TELA

Going concern statement

TELA's 10-Q filed Nov 10, 2026 states:

Notes to Unaudited Interim Consolidated Financial Statements (Continued) These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on TELA

TELA mentioned in Kresmion daily briefs

TELA against its peers

TELA's operating margin of -42.0% ranks in the 69th percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.

MetricTELAPeer medianPercentilen
Revenue FY80.3M USD13.0M USD9023
Gross margin67.7%45.4%8319
Operating margin-42.0%-218.9%6923
Net margin-48.4%-140.3%6523
Return on equity-615.1%-88.4%1319
1 year-28.2%-42.5%6322

Peers (23): ELUT, RPID, XTNT, NSPR, NSYS, QTI, NNOX, SRTS, MDAI, MYO, POSC, COCH, FOFA, PETV, MDNC, PMI, EBRCZ, RDGL, HYPR, ECOR, LNSR, SERA, CVRX. Left out: TLTFF (no annual filing), RTGN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (TELA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in TELA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TELA in the last 180 days.

Upstream: SEC EDGAR filings for TELA

Kresmion, "TELA Bio, Inc. (TELA) institutional holdings and SEC filings", data as of 2026-11-11, https://kresmion.com/research/TELA. Upstream data: SEC EDGAR filings for TELA.

Link to this data (HTML):

<a href="https://kresmion.com/research/TELA">TELA Bio, Inc. (TELA) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow TELA on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TELA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the TELA dossier
Share

The TELA intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.